According to Zacks, “RedHill Biopharma focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases, including cancer. RedHill’s proprietary pipeline includes: RHB-105 – a combination therapy for H.pylori infection; RHB-104 – a combination therapy for Crohn’s disease and multiple sclerosis; BEKINDA – a once-daily oral formulation of ondansetron for acute gastroenteritis and IBS-D; RHB-106 – an encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals; YELIVA – an orally-administered first-in-class SK2 selective inhibitor targeting oncology, inflammatory and gastrointestinal indications; MESUPRON – a uPA inhibitor targeting gastrointestinal and other solid tumors; RP101 – currently subject to an option-to-acquire, Hsp27 inhibitor targeting gastrointestinal cancers; RIZAPORT – an oral thin film formulation of rizatriptan for acute migraines. “
Separately, FBR & Co increased their price target on RedHill Biopharma Ltd – from $33.00 to $36.00 and gave the company an outperform rating in a research note on Wednesday, July 27th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $26.00.
Shares of RedHill Biopharma Ltd – (NASDAQ:RDHL) traded down 0.47% on Wednesday, hitting $14.67. The company had a trading volume of 3,026 shares. The company has a 50 day moving average of $15.01 and a 200-day moving average of $12.67. RedHill Biopharma Ltd – has a 12-month low of $8.10 and a 12-month high of $16.54. The company’s market cap is $186.81 million.
RedHill Biopharma Ltd – (NASDAQ:RDHL) last released its quarterly earnings results on Wednesday, July 27th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.52. On average, analysts forecast that RedHill Biopharma Ltd – will post ($2.06) earnings per share for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Ingalls & Snyder LLC purchased a new position in shares of RedHill Biopharma Ltd – during the second quarter worth $451,000. Royal Bank of Canada raised its position in shares of RedHill Biopharma Ltd – by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock worth $259,000 after buying an additional 191 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new position in shares of RedHill Biopharma Ltd – during the second quarter worth $142,000. Finally, Van ECK Associates Corp raised its position in shares of RedHill Biopharma Ltd – by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock worth $105,000 after buying an additional 138 shares in the last quarter.
About RedHill Biopharma Ltd –
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RedHill Biopharma Ltd - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd - and related companies with MarketBeat.com's FREE daily email newsletter.